ALK and non-small cell lung carcinoma: Treatment of advanced stage <i>anaplastic lymphoma kinase</i> (<i>ALK</i>) positive non-small cell lung cancer (NSCLC) with ALK tyrosine kinase inhibitors (TKIs) has been shown to be superior to standard platinum-based chemotherapy.